TITLE:
Successful Treatment of Suborbital Pyogenic Granuloma with Topical Imiquimod
AUTHORS:
George Badavanis, Efstathia Pasmatzi, Alexandra Monastirli, Dionysios Tsambaos
KEYWORDS:
Pyogenic Granuloma, Imiquimod, Children, Angiogenesis
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.7 No.1,
January
9,
2018
ABSTRACT: Pyogenic granuloma (PG) is a benign vascular proliferation of the skin and mucosae, that has been treated with different regimens with variable success and recurrence rates; however, the management of PG still remains a challenging issue, particularly in children and in adult cases with lesions localized at sites difficult to access. Imiquimod, a member of the imidazoquinoline family of immune response modifiers, is a topically applicable TLR-7/8 agonist that reveals potent antiviral, antitumor, immunoregulatory and antiangiogenic properties. In the present paper we report the case of a 9-year old boy with suborbital pyogenic granuloma, successfully treated with topical daily application of imiquimod 5% cream without occlusion. 8 weeks after onset of topical imiquimod treatment a complete resolution of the lesion without any scarring was observed. No systemic side effects were seen and the patient remained well throughout the course of therapy. He is presently completing a 15-month follow-up and has revealed no relapse. The findings of the present study suggest that topical imiquimod is a safe, effective and well-tolerated treatment for PG in children, even at difficult to treat areas like the suborbital region.